Peel Hunt restated their buy rating on shares of Udg Healthcare (LON:UDG) in a research note issued to investors on Thursday morning.
A number of other equities research analysts have also recently commented on the company. Numis Securities reissued a reduce rating on shares of Udg Healthcare in a research note on Wednesday, August 8th. Jefferies Financial Group raised Udg Healthcare to a buy rating and lowered their price target for the company from GBX 895 ($11.69) to GBX 890 ($11.63) in a report on Thursday, August 9th. Barclays reaffirmed an equal weight rating on shares of Udg Healthcare in a report on Friday, September 28th. Royal Bank of Canada initiated coverage on Udg Healthcare in a report on Wednesday, November 7th. They set an outperform rating and a GBX 800 ($10.45) price target on the stock. Finally, Liberum Capital reaffirmed a buy rating on shares of Udg Healthcare in a report on Thursday, November 22nd. Four analysts have rated the stock with a hold rating and five have given a buy rating to the company. The company currently has an average rating of Buy and an average price target of GBX 826.22 ($10.80).
Shares of LON UDG traded up GBX 13.50 ($0.18) during trading on Thursday, reaching GBX 642.50 ($8.40). The company had a trading volume of 863,444 shares, compared to its average volume of 981,360. Udg Healthcare has a 12-month low of GBX 690 ($9.02) and a 12-month high of GBX 963 ($12.58).
The company also recently announced a dividend, which will be paid on Monday, February 4th. Shareholders of record on Thursday, January 10th will be issued a $0.12 dividend. This is an increase from Udg Healthcare’s previous dividend of $0.04. The ex-dividend date of this dividend is Thursday, January 10th. This represents a yield of 1.55%.
In other Udg Healthcare news, insider Myles Lee sold 6,000 shares of the stock in a transaction dated Tuesday, November 27th. The stock was sold at an average price of GBX 590 ($7.71), for a total value of £35,400 ($46,256.37). Also, insider Peter Gray bought 14,000 shares of the stock in a transaction on Wednesday, September 19th. The stock was purchased at an average cost of GBX 631 ($8.25) per share, for a total transaction of £88,340 ($115,431.86).
Udg Healthcare Company Profile
UDG Healthcare plc, together with its subsidiaries, provides advisory, communication, commercial, clinical, and packaging services to the healthcare industry in the Republic of Ireland, the United Kingdom, North America, and internationally. The company operates through three segments: Ashfield, Sharp, and Aquilant.
Recommended Story: NASDAQ
Receive News & Ratings for Udg Healthcare Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Udg Healthcare and related companies with MarketBeat.com's FREE daily email newsletter.